Oncternal Therapeutics, Inc. – NASDAQ:ONCT
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 3 hours
Oncternal Therapeutics stock price monthly change
-7.36%
month
Oncternal Therapeutics stock price quarterly change
-12.73%
quarter
Oncternal Therapeutics stock price yearly change
+1893.25%
year
Oncternal Therapeutics key metrics
Market Cap | 1.55M |
Enterprise value | N/A |
P/E | -0.38 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 0.25 |
PEG ratio | 0.01 |
EPS | -12.34 |
Revenue | 1.15M |
EBITDA | -38.35M |
Income | -36.38M |
Revenue Q/Q | 180.29% |
Revenue Y/Y | 21.54% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | -3331.89% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeOncternal Therapeutics stock price history
Oncternal Therapeutics stock forecast
Oncternal Therapeutics financial statements
| Jun 2023 | 106K | -8.96M | -8458.49% |
|---|---|---|---|
| Sep 2023 | 179K | -9.86M | -5509.5% |
| Dec 2023 | 297K | -9.16M | -3085.52% |
| Mar 2024 | 569K | -8.38M | -1474.17% |
| Dec 2023 | 297K | -9.16M | -3085.52% |
|---|---|---|---|
| Mar 2024 | 569K | -8.38M | -1474.17% |
| Oct 2025 | 200K | -5.91M | -2959% |
| Dec 2025 | 200K | -6.06M | -3032.98% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 50773000 | 5.58M | 11.01% |
|---|---|---|---|
| Sep 2023 | 43195000 | 6.19M | 14.35% |
| Dec 2023 | 36729000 | 6.67M | 18.18% |
| Mar 2024 | 29141000 | 6.21M | 21.33% |
| Jun 2023 | -9.26M | 13.85M | -1K |
|---|---|---|---|
| Sep 2023 | -5.51M | 4.65M | -49K |
| Dec 2023 | -6.41M | -1.80M | -1K |
| Mar 2024 | -7.43M | 7.22M | -87K |
Oncternal Therapeutics alternative data
| Aug 2023 | 30 |
|---|---|
| Sep 2023 | 30 |
| Oct 2023 | 30 |
| Nov 2023 | 30 |
| Dec 2023 | 30 |
| Jan 2024 | 30 |
| Feb 2024 | 30 |
| Mar 2024 | 27 |
| Apr 2024 | 27 |
| May 2024 | 27 |
| Jun 2024 | 27 |
| Jul 2024 | 27 |
Oncternal Therapeutics other data
16.34%
-2.43%
of ONCT is owned by hedge funds
8.85M
-540.18K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jun 2023 | 28000 | 0 |
| Feb 2024 | 980 | 980 |
| Mar 2024 | 6914 | 0 |
| Apr 2024 | 3086 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | WILLS ROBERT JAMES director | Common Stock | 3,086 | $8.96 | $27,654 | ||
Purchase | WILLS ROBERT JAMES director | Common Stock | 6,914 | $8.48 | $58,603 | ||
Purchase | HALE DAVID F director | Common Stock | 266 | $9.04 | $2,405 | ||
Purchase | HALE DAVID F director | Common Stock | 714 | $9.04 | $6,455 | ||
Sale | WILLS ROBERT JAMES director | Common Stock | 980 | $9.04 | $8,859 | ||
Purchase | KAUFMANN GUNNAR F. officer: Chief Sc.. | Common Stock | 3,000 | $0.36 | $1,080 | ||
Purchase | KAUFMANN GUNNAR F. officer: Chief Sc.. | Common Stock | 25,000 | $0.35 | $8,750 | ||
Purchase | YAZJI SALIM officer: Chief Medical Officer | Common Stock | 5,000 | $0.3 | $1,500 | ||
Purchase | BREITMEYER JAMES B director, officer.. | Common Stock | 47,750 | $0.3 | $14,277 | ||
Purchase | BREITMEYER JAMES B director, officer.. | Common Stock | 2,250 | $0.29 | $653 |
| Patent |
|---|
Grant Utility: Uses of indolinone compounds Filling date: 13 Apr 2020 Issue date: 29 Mar 2022 |
Application Filling date: 8 Jul 2021 Issue date: 27 Jan 2022 |
Grant Utility: Compounds for treatment of cancer Filling date: 21 Feb 2019 Issue date: 10 Aug 2021 |
Application Filling date: 29 Jan 2020 Issue date: 28 Jan 2021 |
Grant Utility: Compounds for treatment of cancer Filling date: 16 Jan 2018 Issue date: 15 Dec 2020 |
Application Filling date: 13 Apr 2020 Issue date: 13 Aug 2020 |
Grant Utility: Indoline analogs and uses thereof Filling date: 3 Jun 2019 Issue date: 14 Jul 2020 |
Grant Utility: Uses of indolinone compounds Filling date: 27 Aug 2018 Issue date: 12 May 2020 |
Application Filling date: 3 Jun 2019 Issue date: 7 Nov 2019 |
| Quarter | Transcript |
|---|---|
| Q1 2024 9 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 7 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 9 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 10 Aug 2023 | Q2 2023 Earnings Call Transcript |
Oncternal Therapeutics: Selling For Under Cash Value
Oncternal Therapeutics:Â As Phase 2 Study Matures, Data Continues To Improve
Celularity: Funds Infusion Needed ASAP To Advance
Oncternal Therapeutics: Trading Near Cash With Impressive Results
Week 46 MDA Breakout Stocks - November 2021: Short-Term Picks To Give You An Edge
Context Therapeutics: A New Biotech Issue With A Low Valuation And Significant Potential
Why I Added Oncternal Therapeutics To My Watchlist
Oncternal Therapeutics: New Data Continues To Derisk
ASCO 2021: A Plethora Of Cancer Therapeutic Investment Ideas
-
When is Oncternal Therapeutics's next earnings date?
Unfortunately, Oncternal Therapeutics's (ONCT) next earnings date is currently unknown.
-
Does Oncternal Therapeutics pay dividends?
No, Oncternal Therapeutics does not pay dividends.
-
How much money does Oncternal Therapeutics make?
Oncternal Therapeutics has a market capitalization of 1.55M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 47.32% to 785K US dollars.
-
What is Oncternal Therapeutics's stock symbol?
Oncternal Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "ONCT".
-
What is Oncternal Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Oncternal Therapeutics?
Shares of Oncternal Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Oncternal Therapeutics's key executives?
Oncternal Therapeutics's management team includes the following people:
- Dr. James B. Breitmeyer Pres, Chief Executive Officer & Director(age: 71, pay: $781,800)
- Dr. Gunnar F. Kaufmann Ph.D. Chief Scientific Officer(age: 49, pay: $525,890)
-
How many employees does Oncternal Therapeutics have?
As Jul 2024, Oncternal Therapeutics employs 27 workers.
-
When Oncternal Therapeutics went public?
Oncternal Therapeutics, Inc. is publicly traded company for more then 21 years since IPO on 3 Feb 2004.
-
What is Oncternal Therapeutics's official website?
The official website for Oncternal Therapeutics is oncternal.com.
-
Where are Oncternal Therapeutics's headquarters?
Oncternal Therapeutics is headquartered at 12230 El Camino Real, San Diego, CA.
-
How can i contact Oncternal Therapeutics?
Oncternal Therapeutics's mailing address is 12230 El Camino Real, San Diego, CA and company can be reached via phone at 858 434 1113.
Oncternal Therapeutics company profile:
Oncternal Therapeutics, Inc.
oncternal.comExchange:
NASDAQ
Full time employees:
27
Industry:
Biotechnology
Sector:
Healthcare
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.
12230 El Camino Real
San Diego, CA 92130
San Diego, CA 92130
CIK: 0001260990
ISIN: US68236P2065
CUSIP: 68236P107
